Navigation Links
Biomarkers May Predict Alzheimer's
Date:7/21/2009

Proteins in spinal fluid may help diagnose disease early, study shows,,

TUESDAY, July 21 (HealthDay News) -- Certain proteins found in cerebrospinal fluid may accurately identify the people with mild cognitive impairment who are most likely to develop Alzheimer's disease, a new study finds.

Changes in the chemistry of cerebrospinal fluid have been identified as early signs of Alzheimer's disease. If and when treatments are available for Alzheimer's, diagnosing the disease early may help prevent it from developing, experts say.

"We confirmed, in a large multi-center study, that proteins in cerebrospinal fluid identify early-stage Alzheimer's disease, as suggested by previous smaller studies," said lead researcher Dr. Niklas Mattsson, from the Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital in Molndal, Sweden.

"These proteins may be used in research, in particular in drug trials, and also as a complement to clinical diagnostics, in particular when disease-modifying drugs become available," he said.

The report is published in the July 22/29 issue of the Journal of the American Medical Association.

For the study, Mattsson's team studied the accuracy of using three biomarkers found in spinal fluid in predicting Alzheimer's diseases. The biomarkers are beta-amyloid1-42 (Aβ42), total tau protein (T-tau), and tau phosphorylated at position threonine 181 (P-tau).

The researchers tested for these biomarkers in 750 people with mild cognitive impairment, 529 people with Alzheimer's disease and 304 healthy people. After two years, 271 of those with mild cognitive impairment progressed to Alzheimer's disease and 59 developed other dementias.

The researchers found that people who developed Alzheimer's had lower levels of Aβ42 and higher levels of P-tau and T-tau compared with patients with mild cognitive impairment who did not develop Alzheimer's.

Mattsson's group found these biomarkers were highly accurate in predicting which patients would develop Alzheimer's disease. "The cerebrospinal fluid proteins Aβ42, T-tau, and P-tau are useful in diagnosis of early-stage Alzheimer's disease," Mattsson noted.

Dr. Sam Gandy, the Mount Sinai Professor in Alzheimer's Disease Research at Mount Sinai School of Medicine in New York City, said this study really quantifies the accuracy of these tests in predicting Alzheimer's.

"There have been a number of smaller reports that Aβ falls and P-tau rises as the clinical course progresses from aging to mild cognitive impairment to Alzheimer's," Gandy said. "The sensitivities and specificities of these smaller studies have varied widely."

This larger study is definitive in establishing sensitivity and specificity that are somewhat lower than those reported by the smaller studies, Gandy said. "The larger study also points up the importance of harmonizing assays across multiple study sites in order to optimize the sensitivity and specificity."

Maria Carrillo, director of medical and scientific relations at the Alzheimer's Association, hopes that one day Alzheimer's can be screened for as routinely as cholesterol levels are checked today.

"We are very excited that cerebrospinal fluid biomarkers are holding up in terms of their specificity and sensitivity in diagnosing the disease early," Carrillo said. "The next step is to make sure these tests are standardized so that the test will mean the same thing, no matter where it is taken."

If these tests are standardized, it could be a biomarker that identifies the disease, Carrillo said. "If over the next two or three years we also have a therapy, then we need to examine how that therapy works in an incipient form of Alzheimer's, not once those memories have already started fading," she said.

More information

For more information on Alzheimer's disease, visit the Alzheimer's Association.



SOURCES: Niklas Mattsson, M.D., Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden; Maria Carrillo, Ph.D., director, medical and scientific relations, Alzheimer's Association; Samuel Gandy, M.D., Ph.D., Mount Sinai Professor in Alzheimer's Disease Research, Mount Sinai School of Medicine, New York City; July 22/29, 2009, Journal of the American Medical Association


'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
2. Biomarkers predict brain tumors response to therapy
3. Novel biomarkers in heart failure
4. Biomarkers May Help Measure Rate of Decline in Dementia
5. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
6. BioTech Firm Decodes Current Swine Flu BioMarkers
7. Biomarkers May Predict Aggressiveness of Prostate Cancer
8. Vitamin D Linked to HDL Cholesterol - Shaklee Corporation Research Links Vitamin D with Key Biomarkers for Metabolic Syndrome and Heart Disease
9. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
10. Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
11. Biomarkers detected for Chikungunya fever
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarkers May Predict Alzheimer's 
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: